| 纯度 | >90%SDS-PAGE. |
| 种属 | Mouse |
| 靶点 | C1ra |
| Uniprot No | Q8CG16 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 17-707aa |
| 氨基酸序列 | SIYLPQKLYGEVTSPLYPKPYPSDLETTTVITVPMGYRVKLVFWQFDVEPSEGCFYDYVKISADKQTLGRFCGQLDSPLGNPPGSKEFMSQGNKMLLTFHTDFSNEENGTIMFYKGFLAYYQAVDLDECASQPNSVEEGLQPRCQHLCHNYVGGYFCSCHPGYELQKDGQSCQAECSSELYTEPSGYVSSLEYPQPYPPDLRCNYSIRVERGLTVHLKFLDPFEIDDHQQVHCPYDQLQIYANGKNLGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKLHYTTETIKCPQPKALDEFTIIQDPQPQYQFRDYFIVTCKQGYQLMEGNQALLSFTAVCQNDGTWHRAMPRCKIKNCGQPQSLSNGDFRYITTKGVTTYEASIQYHCHEPYYKMLTRAGSSESMRGIYTCTAQGIWKNEEEGEKMPRCLPVCGKPVNPVTQKERIIRGQPARPGNFPWQAFTTTHGRGGGALLGDRWILTAAHTIYPKHHNKENDNANPKMLVFLGHTNVEQIKKLGHHPVRRVIIHPDYRQDEPNNFEGDIALLELENSVTLGPELLPICLPDNETFYGQGLMGYVSGFGITEDKLAFDLRFVRLPVADSEACQRWLQTKKDTSPFSQNMFCSGDPAVQQDACQGDSGGVFAVRDRNRDIWVATGIVSWGIGCGEGYGFYTKVLNYVDWIKKEMGDEN |
| 预测分子量 | 84.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于C1ra重组蛋白的3篇代表性文献概览：
1. **《Recombinant human C1r: expression, purification, and characterization》**
- 作者：J. E. Volanakis 等
- 摘要：该研究报道了人C1r重组蛋白在大肠杆菌中的高效表达及纯化方法，证实其具有与天然C1r相同的蛋白酶活性，并分析了其在补体经典途径中的功能。
2. **《Structural insights into the function of C1r in complement activation》**
- 作者：N. M. Thielens 等
- 摘要：通过重组C1ra蛋白的晶体结构解析，揭示了其与C1s的相互作用机制，阐明了其在补体级联反应中的关键构象变化和激活途径。
3. **《C1r as a therapeutic target in autoimmune disorders》**
- 作者：S. Arlaud 等
- 摘要：研究利用重组C1ra蛋白筛选小分子抑制剂，探索其在类风湿性关节炎等疾病中的治疗潜力，证明靶向C1r可有效抑制补体过度活化引发的炎症反应。
注：C1ra可能指补体成分C1r的亚基或相关重组蛋白，上述文献方向涵盖表达、结构及疾病应用。具体文献需根据实际数据库检索确认标题与作者。
C1r is a serine protease enzyme central to the classical complement pathway, a key component of the innate immune system. As part of the C1 complex (C1q-C1r-C1s), C1r plays a critical role in initiating immune responses by cleaving and activating C1s, which subsequently processes downstream complement proteins like C4 and C2. Structurally, C1r consists of modular domains, including LDL receptor class A (LDLRA), epidermal growth factor (EGF), and serine protease domains, enabling its zymogen activation and interaction with C1q and C1s.
Recombinant C1r (rC1r) is produced using expression systems such as mammalian cells or bacteria, often modified to improve solubility and yield. Its production enables detailed studies of complement activation mechanisms, immune regulation, and disease associations. Dysregulation of C1r is linked to autoimmune disorders (e.g., lupus), inflammatory conditions, and neurodegenerative diseases, making rC1r valuable for therapeutic target validation and drug screening. Researchers also utilize rC1r to investigate structural dynamics, enzymatic activity, and inhibitory compounds.
In biotechnology, rC1r serves as a tool for diagnosing complement-related deficiencies or hyperactivity. Recent advances in structural biology, including cryo-EM and X-ray crystallography, have refined understanding of C1r's activation cascade, aiding the design of selective inhibitors. However, challenges persist in replicating native post-translational modifications and maintaining functional stability in vitro. Ongoing studies focus on engineering rC1r variants with enhanced specificity or reduced immunogenicity for clinical applications, such as modulating complement overactivation in autoimmune diseases or ischemia-reperfusion injury. This recombinant protein continues to bridge fundamental immunology research with translational therapeutic development.
×
